141 related articles for article (PubMed ID: 1156055)
1. Response to dopamine hydrochloride in the hepatorenal syndrome.
Bennett WM; Keeffe E; Melnyk C; Mahler D; Rösch J; Porter GA
Arch Intern Med; 1975 Jul; 135(7):964-71. PubMed ID: 1156055
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and experimental investigations of the effect of dopamine on haemodynamics and function of kidney and liver (author's transl)].
Peschl L
Wien Klin Wochenschr Suppl; 1978; 86():1-33. PubMed ID: 274863
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of hepatorenal syndrome with dopamine and bromocriptine].
Uribe M; Moreno Berthier J; Guevara L; Ramírez-Acosta J; Márquez MA; Arce A
Rev Gastroenterol Mex; 1979; 44(2):63-6. PubMed ID: 379956
[TBL] [Abstract][Full Text] [Related]
4. [The simultaneous investigation of liver and kidney function in the presence of dopamine (author's transl)].
Mostbeck A; Peschl L; Schüller J; Neumayr A
Wien Klin Wochenschr; 1975 Oct; 87(19):639-42. PubMed ID: 1226762
[TBL] [Abstract][Full Text] [Related]
5. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P
Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
[TBL] [Abstract][Full Text] [Related]
6. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
7. Impact of pretransplant renal function on survival after liver transplantation.
Gonwa TA; Klintmalm GB; Levy M; Jennings LS; Goldstein RM; Husberg BS
Transplantation; 1995 Feb; 59(3):361-5. PubMed ID: 7871566
[TBL] [Abstract][Full Text] [Related]
8. [Decrease in medio-renal and cortical renal blood flow in liver cirrhosis. Relationships with changes in systemic hemodynamics].
Zuin R; Merkel C; Grassetto M; Milani L; Merlo A; Gatta A
Minerva Nefrol; 1979; 26(1):41-4. PubMed ID: 381991
[No Abstract] [Full Text] [Related]
9. Effects of dopamine on renal function in patients with cirrhosis.
Barnardo DE; Baldus WP; Maher FT
Gastroenterology; 1970 Apr; 58(4):524-31. PubMed ID: 5438003
[No Abstract] [Full Text] [Related]
10. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
11. Investigation of intrarenal blood flow and urine flow aspects by scintillation camera.
Kawamura J; Hosokawa S; Yoshida O; Ishii Y; Torizuka K
Invest Urol; 1977 Jan; 14(4):263-8. PubMed ID: 836463
[TBL] [Abstract][Full Text] [Related]
12. Low-dose dopamine infusion in cirrhosis with refractory ascites.
Lin SM; Lee CS; Kao PF
Int J Clin Pract; 1998; 52(8):533-6. PubMed ID: 10622049
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and functional aspects of the kidney in relation to renal and intrarenal hemodynamic changes during hepatic cirrhosis].
Gatta A; Merkel C; Milani L; Caregaro L; Grassetto M; Lauro S; Zuin R
Minerva Nefrol; 1979; 26(1):37-40. PubMed ID: 381990
[No Abstract] [Full Text] [Related]
14. Renal function and structure in subacute hepatic failure.
Bal C; Longkumer T; Patel C; Gupta SD; Acharya SK
J Gastroenterol Hepatol; 2000 Nov; 15(11):1318-24. PubMed ID: 11129228
[TBL] [Abstract][Full Text] [Related]
15. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease.
Koppel MH; Coburn JW; Mims MM; Goldstein H; Boyle JD; Rubini ME
N Engl J Med; 1969 Jun; 280(25):1367-71. PubMed ID: 4890476
[No Abstract] [Full Text] [Related]
16. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
17. Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis.
Salerno F; Incerti P; Badalamenti S; Lorenzano E; Graziani G; Morganti A; Ghirardi P
Arch Intern Med; 1990 Jan; 150(1):65-9. PubMed ID: 1967522
[TBL] [Abstract][Full Text] [Related]
18. [Morpho-functional study of the kidney in patients with kidney disease and liver disease with magnetic resonance].
Shariat Razavi I; Stacul F; Cova M; Artero M; Carraro M; Malalan F; Pozzi Mucelli R; Dalla Palma L
Radiol Med; 1998; 95(1-2):72-81. PubMed ID: 9636731
[TBL] [Abstract][Full Text] [Related]
19. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Al Bokharhii J; Pappas C; Katsaraki A; Tsianos EV
Am J Gastroenterol; 2005 Apr; 100(4):879-85. PubMed ID: 15784036
[TBL] [Abstract][Full Text] [Related]
20. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
